Angiodynamics announces ce mark approval in europe for alphavac f18⁸⁵ system

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced european ce mark approval of the alphavac f1885 system for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (pe). “the ce mark represents a major.
ANGO Ratings Summary
ANGO Quant Ranking